Monthly Archives: December 2015

SOUTH AFRICAN PRESIDENT RECEIVES FINAL REPORT ON 1999 ARMS DEAL

South African President Jacob Zuma has received the final report from the Commission of Inquiry into the 1999 Strategic Defence Procurement Packages (SDPP), commonly known as the Arms Deal Commission.

The President received the report in Durban on Wednesday from Judge Willie Seriti, accompanied by Judge Thekiso Musi, a member of the Commission.

The Commission, chaired by Judge Seriti, was established by the President in September 2011 to investigate allegations of fraud, corruption, impropriety or irregularity in the arms procurement process.

President Zuma expressed his gratitude to Judge Seriti and all members of the Commission for the work done in ensuring the successful conclusion of the work of the Commission.

The President also thanked all witnesses who participated in the Commission and who have contributed to its success.

(Eds note: The Defence Department's SDPP aimed to modernise its defence equipment, which included the purchase of corvettes, submarines, light utility helicopters, lead-in fighter trainers and advanced light fighter aircraft at a cost of 30 billion Rand).

SOURCE: SABC

Les équipements de construction de XCMG en voie d’appuyer le ...

BANGKOK, 29 décembre 2015 / PRNewswire — XCMG, fabricant mondial de matériel de construction et d’exploitation minière s’est joint à la cérémonie officielle du lancement du projet de chemin de fer Chine – Thaïlande, cérémonie qui a eu lieu le 19 décembre à la gare de Chiang Rak Noi dans la province thaïlandaise d’Ayutthaya. Le projet de voie ferrée à grande vitesse s’étend sur 845 kilomètres à travers 10 provinces en Thaïlande. Les trains pourront atteindre une vitesse jusqu’à 180 kilomètres à l’heure, avec un potentiel d’amélioration permettant d’envisager 250 kilomètres à l’heure. Il est planifié de terminer les quatre tronçons de construction de la voie ferrée pour une mise en exploitation à l’année 2020. Liu Jiansen, président assistant de XCMG et directeur général de XCMG Import and Export Co., Ltd, a assisté à cette cérémonie exceptionnelle. « Figurant parmi les 5 premiers constructeurs au monde d’engins et de solutions d’équipement pour la construction, XCMG va fournir la meilleure qualité de machines et de matériels pour venir en appui au projet ferroviaire entre la Chine et la Thaïlande, » a-t-il déclaré. « Notre ligne de production est la plus exhaustive et elle possède des ensembles complets de machinerie et d’équipement pour la construction de lignes et de ponts de chemin de fer. » Liu a fait observer que l’idée de base dans cette participation au projet ferroviaire Chine – Thaïlande est au départ d’aider à améliorer le niveau d’infrastructure en Thaïlande ainsi que le niveau de vie des personnes dans cette nation. Dans sa détermination à élever la qualité de vie, XCMG a contribué à d’autres projets d’infrastructure autour du monde. Début 2015, XCMG a exporté des engins, parmi lesquels des épandeurs régleurs, pour apporter son assistance à la construction de la route nationale 6 au Cambodge. En 2011, ce sont 6 025 unités produites chez XCMG, dont des camions-pompes, des tombereaux, des chargeurs et des rouleaux, qui à Caracas au Venezuela ont aidé à lancer les opérations pour la « Mission de logement au Venezuela ». XCMG appuie également une vaste partie du marché africain avec des commandes majeures telles que la fourniture d’ensembles complets de matériel pour le chemin de fer Mombasa – Nairobi, d’engins pour l’Éthiopie, de même que 100 m de plate-forme aérienne pour camions de pompiers en Angola. « Nos produits et services sont essentiels pour que les pays en développement réalisent la construction de leurs infrastructures afin de stimuler le développement économique tout en apportant de nouvelles possibilités d’emploi, » a déclaré Liu. « À l’avenir, XCMG continuera à soutenir de tels projets autour du globe pour assurer des moyens de transport plus pratiques et de meilleures conditions d’existence grâce à un matériel de pointe. » Pour davantage de renseignements, veuillez visiter : www.xcmg.com, ou les pages de XCMG sur Facebook, Twitter et YouTube.

XCMG’s Construction Machinery on Track to Support China-Thailand ...

BANGKOK, Dec. 29, 2015 / PRNewswire — Global construction and mining equipment manufacturer XCMG joined the official launching ceremony of the China-Thailand railway project that was held at Chiang Rak Noi Station in central Thailand’s Ayutthaya province on December 19.

The high-speed railroad project spanning 845 kilometers through 10 provinces in Thailand will allow trains to operate at top speeds of 180 kilometers per hour with potential upgrade possibility to 250 kilometers per hour. The four sections of railroad construction are planned to be completed and put into operation by year 2020.

Liu Jiansen, assistant president of XCMG and general manager of XCMG Import and Export Co., Ltd, attended the groundbreaking ceremony.

“As one of the top 5 construction machinery manufacturers and equipment solution suppliers in the world, XCMG will be providing the best quality machinery and equipment to assist the construction of China-Thailand railway project,” he said, “our most comprehensive production line possess complete sets of machineries and equipment for railroad and bridge construction.”

Liu remarked that the initial idea behind participating in the China-Thailand railway project is to help improve the infrastructure level of Thailand as well as people’s living standards in this nation. Committed to boosting quality of life, XCMG has also been assisting infrastructure projects around the world.

Early in 2015, XCMG has exported machineries including pavers to assist the construction of the National Highway 6 in Cambodia. In 2011, 6,025 units of XCMG products including concrete pump trucks, dump trucks, loaders and rollers launched operations for the “Venezuela Housing Project” in Caracas, Venezuela.

XCMG also sustains the largest share of the African market with major orders such as supplying complete sets of equipment to the Mombasa-Nairobi Railway, machinery to Ethiopia as well as 100m aerial platform fire trucks to Angola.

“Our products and service are essential for developing countries to complete their infrastructure construction, which can stimulate the economic development as well as bringing new job opportunities,” Liu said. “In the future, XCMG will continue to support such projects around the world to provide more convenient transportation as well as better living conditions with state-of-the-art equipment.”

More information, please visit: www.xcmg.com, or XCMG pages on Facebook, Twitter and Youtube.

Nanda Muruttettuwegama assumes duties as Lankapuvath Chairman

Dec 24, Colombo: The Incumbent Chairman of Sri Lanka Broadcasting   Corporation (SLBC) Attorney-at-Law and Legal Educationist, Mr. Nanda Muruttettuwegama assumed duties as the new Chairman of the Lankapuvath Ltd, the National News Agency of Sri Lanka on Wednesday (23).

Expressing his views at the occasion, Mr. Muruttettuwegama stressed that he will do his utmost best to restore the National News Agency of Sri Lanka to its former glory which had weakened due to various reasons in the past.

Mr. Muruttettuwegama, who is the Managing Director of Centre for Professional Studies (CfPS) Law School, has solidified his role as one of the most prominent lawyers in the island-nation. He also holds the position as the Chairman of the Sri Lanka Broadcasting Corporation (SLBC) in addition to the Chairmanship of the Lankapuvath Ltd.

Lankapuvath Ltd. was established parallel to National News Agencies of India (Press Trust of India), Malaysia (Bernama News Agency), People’s Republic of China (Xinhua News Agency) etc. and commenced operations in 1978 as a result of an idea generated at the United Nations Educational, Scientific and Cultural Organization (UNESCO). Since then, Lankapuvath Ltd. has remained and operates under its agreement with the Ministry of Parliamentary Reforms and Mass Media in Sri Lanka, as the National News Agency.

Late Veteran Journalist Esmond Wickremesinghe, father of the incumbent Prime Minister Ranil Wickremesinghe has served as the first Chairperson of Lankapuvath Ltd.

The company has five shareholders and primary national media establishments are among them. Namely; Sri Lanka Broadcasting Corporation (SLBC), Sri Lanka Rupavahini Corporation (SLRC), The Independent Television Network (ITN), Associated Newspapers of Ceylon Limited (ANCL) and The Express Newspapers (Ceylon) Limited.

Lankapuvath National News Agency currently operates as an international news provider for AsiaNet Pakistan (Pakistan), Factiva Dow Jones & Company (United States), New Delhi Television Ltd. (India), Organisation of Asia-Pacific News Agencies (OANA, Russian Federation), and Sputnik News Agency (Russian Federation).

 

Research and Markets: Pulmonary Tuberculosis Global Clinical Trials ...

Research and Markets (http://www.researchandmarkets.com/research/r7hfpd/pulmonary) has announced the addition of the "Pulmonary Tuberculosis Global Clinical Trials Review, H2, 2014" report to their offering.

This clinical trial report provides data on the Pulmonary Tuberculosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pulmonary Tuberculosis.

It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pulmonary Tuberculosis.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope of the Report:

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to Buy:

Understand the dynamics of a particular indication in a condensed manner

Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

Obtain discontinued trial listing for trials across the globe

Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

For more information visit http://www.researchandmarkets.com/research/r7hfpd/pulmonary

Contacts

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Sector: Clinical Trials

Source: Research and Markets

The University of Liverpool Online Master of Public Health Receives ...

LIVERPOOL, England, Dec. 21, 2015 / PRNewswire  — The University of Liverpool’s online Master of Public Health (MPH) programme has been accredited by the Agency for Public Health Education Accreditation (APHEA), a globally recognised accrediting body for masters-level public health programmes. APHEA is a partnership between five leading European public health associations to promote quality education for public health professionals worldwide, and accreditation means the online MPH programme meets international quality standards.

University of Liverpool Online Programmes.

Logo – http://photos.prnewswire.com/prnh/20140325/CL90134LOGO

Accreditation provides University of Liverpool online MPH graduates with the opportunity to gain a degree that employers will recognise as independently assessed and one that provides the essential competencies required by public health professionals worldwide. The accreditation process involved a rigorous assessment of the online MPH across seven criteria, and the assessment was based in part on feedback from current students and teaching staff.

“APHEA accreditation is important for our students. It means they can gain a degree that is internationally recognised and with globally transferable skills,” says Dr Francine Watkins, Director of MPH Programmes at the University of Liverpool. “Our online MPH programme is essential for professionals working in health services, government agencies and NGOs. We currently have students from over 100 countries studying at postgraduate level, gaining public health skills and knowledge without needing to take time out from their jobs so they can apply their new knowledge immediately into their practice.”

The University of Liverpool’s online MPH students and graduates include professionals in developed and developing countries around the world working at the front line of public health delivery in areas including healthcare management, health improvement, prevention and health protection. Designed for working professionals, online learning enables students to enjoy an engaging, global and highly collaborative learning experience.

For more information about the University of Liverpool’s online programmes, visit www.university-liverpool-online.com.

About the University of Liverpool Online Programmes
The University of Liverpool ranks in the top 1% of universities worldwide and is a member of the UK’s Russell Group of research-led universities. More than 10,000 students from more than 160 countries are studying for postgraduate certificates, masters and doctoral degrees online with the University of Liverpool. These programmes are provided in partnership with online learning expert, Laureate Online Education. (For more information about Laureate, visit www.laureate.net.)

Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ...

Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM), a clinical-stage autologous cell-therapy company, announced today the Company's progress in expanding the international, multicenter, phase-2 clinical trial of its lead product ACP-01 for critical limb ischemia (CLI) to the United States.

The ongoing phase-2 clinical trial investigates the safety and efficacy of ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are grown from a patient's own blood and, once injected into his or her diseased tissue, are able to support the formation of new blood vessels. The clinical trial currently recruits patient at two sites in Canada and four sites in South Africa.

"After receiving clearance from the FDA to recruit patients in the United States, we've been engaged in a multistep site-initiation process with qualified medical centers that involves executing nondisclosure agreements and discussing our clinical trial protocol," said Dr. Hardean E. Achneck, vice president of clinical research and operations at Hemostemix. "I'm encouraged and inspired by the positive feedback on the design of our clinical trial that we've been receiving from vascular surgeons at such leading U.S. medical centers as Houston Methodist DeBakey Heart & Vascular Center, University of California Davis Vascular Center, Ronald Reagan UCLA Medical Center, Temple University, Malcom Randall Veterans Affairs Medical Center, and Yale University. We are discussing the terms of contractual agreements with some of these sites, and several sites are currently in the process of submitting study documents to their respective institutional review boards."

"Leading medical centers in the United States are increasingly recognizing the groundbreaking potential of our lead product ACP-01 for the treatment of CLI," said Dr. Elmar Burchardt, Hemostemix president and CEO. "There is tremendous need for a therapy that reduces the number of limb amputations and improves survival. ACP-01 gives hope to patients who suffer from CLI and to physicians who lack other treatment options."

About Critical Limb Ischemia (CLI)

CLI is a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. About half of CLI patients either die or require amputation of the affected limb within one year of diagnosis. Demand for a treatment is on the rise, as CLI predominately affects the growing population aged 50 and older.

About Hemostemix

Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, phase-2 clinical trial for patients with CLI. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada.

Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. For more information, visit hemostemix.com or email office@hemostemix.com.

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION

Hemostemix Inc.

Dr. Elmar Burchardt

President and CEO

(617) 500-8401

Hemostemix Inc.

C.W. (Bill) Baker

Chairman of the Board

(403) 818-7672

Source: Hemostemix Inc

Associa Minnesota Looks to Continue 2015 Success into the New Year

Associa Minnesota, formerly Community Development, Inc., would like to formally welcome and announce its 21 communities that joined the Associa family in 2015.

"We're honored that each of these clients chose to work with Associa Minnesota in 2015. Our community managers and operations team truly stepped up to the challenge of partnering with so many new associations," says Associa Minnesota Director of Client Development Jesse Dubuque. "In addition to the new clients in 2015, we also rebranded from Community Development, Inc. to Associa Minnesota and moved into our brand new office in Brooklyn Park and I'm excited to see the team continue these growth opportunities into 2016."

In 2015 Associa Minnesota was chosen to provide full management services, including financial, community management, communications, record-keeping and administrative services to the following communities:

• Bella Vista Community Homeowners' Association

• Boulder Ponds Association

• Bush Terrace Owners' Association

• Cayden Glen Homeowners' Association

• Creekside of Plymouth Homeowners' Association

• Eastview Place Homeowners' Association

• Evergreen Community Association

• Ferndale Terrace Association

• Hunters Pass Estates Homeowners' Association

• Parkview Homeowners' Association

• Powers Lake Townhome Association

• Prairie Village Homeowners' Association

• Ravinia Neighborhood Association

• Remington Coves Bayhomes Association

• Remington Coves Master Association

• Remington Coves Single Family Homes Association

• The Grand Condominium Association

• Villas at Medina Country Club Association

• Villas in the Lakes of Radisson

• Villas of Rush Creek Trail

• Westview Estates Townhome Association

Building and managing successful communities for more than 35 years, Associa is the worldwide leader in community management with over 10,000 employees operating more than 180 branch offices in the United States, Mexico, Canada, the United Arab Emirates and South Africa. Based in Dallas, Texas, our industry expertise, financial strength, and innovation meet the unique needs of clients across the world with customized services and solutions designed to help communities achieve their vision. To learn more about Associa and its charitable organization, Associa Cares, go to www.associaonline.com or www.associacares.com.

Stay Connected:

Facebook: https://www.facebook.com/associa

Twitter: https://twitter.com/associa

LinkedIn: http://www.linkedin.com/company/associa

Pinterest: http://pinterest.com/associa/

YouTube: http://www.youtube.com/associamarketing

Google+: https://plus.google.com/+Associaonline/

Billy Rudolph

+1 (214) 272-4107

Source: Associa